FONDSEN FOCUS

02.02.2021



Carmignac Investissement: Letter from the Portfolio Manager



Carmignac Investissement gained +15.47% in the fourth quarter of 2020 vs +9.91% for the reference indicator*, taking its full-year return to +33.65% vs +6.65% respectively.

The Equity Market

The last quarter of 2020 exhibited strong and broad-based market performance.

Initially, the recovery in equities has been driven by growth stocks from the lows of March. However, in the last months of the year, value stocks rebounded sharply, both in the developed and emerging world. In fact, the news of a Covid 19 vaccine in November acted as an additional boost for markets. The names that had lagged the most in 2020, namely airlines, banks and energy companies, rallied sharply on the back of this news and reduced some of the underperformance that had occurred versus their growth stock counterparts.

Portfolio Management

Over the quarter, the Fund benefited from its wide and diversified geographic exposure. Especially, our high convictions in China recorded substantial gains, leading us to outperform our reference indicator. Also, our investment approach focusing on secular growth has continued to pay off, illustrated by our gains in the technology, healthcare and consumer space. In these sectors, we were able to generate significant alpha thanks to some of the long term thematic we focus on. These include climate change, that led us to invest in electric car companies and battery producers, notably in China. These also include companies with activities revolving around both the use and storage of big data, and many healthcare companies that are under pressure to innovate as populations age and chronic diseases increase. Finally, we added in April/May names that we felt had suffered a lot from the crisis but would benefit from steady reopening of economies. Among them, Amadeus, a Spanish IT provider for the global travel and tourism industry and Safran, a jet engine manufacturer focused on short haul tourism flights. These positions allowed us to mitigate the impact of a value catch up towards the end of the year.

Among our top contributors of the quarter, we note Chinese electric car companies, Nio and Xpeng, up respectively 139% and 177% over the period, and the biotech company Wuxi Biologics, a Chinese platform that offers end-to-end solutions to empower organizations to discover, develop, and manufacture biologics products.

Investment Outlook

2021 will be about the post-COVID economic recovery alongside continuing massive policy support. Yet markets have already adjusted very quickly to this scenario - and in some cases have become overly exuberant. Therefore, we are cautious on high valuation stocks and took profits on the key beneficiaries of the "stay at home" economy and Chinese names.

























Source: Carmignac, 31/12/2020

Other: 4.7% The portfolios of Carmignac funds may change without previous notice. The trademarks and logos are used with the authorisation of the respective entities and do not imply any affiliation with or endorsement by them.

Beyond these short-term considerations, over the long term, we believe secular growth stocks that we find in Tech and Internet, but also Health Care & Consumer, will keep performing well because of their superior growth prospects and business models. In some cases, we can even see a lot of negativity priced into the stocks – around regulation for the GAFA (Google, Amazon, Facebook and Apple) for example – that is likely to lift moving forward when visibility will increase. In addition, secular growth does not exclude cyclicality – there were many opportunities to buy COVID affected companies that combine a secular growth profile with "reopening" cyclicality – like Worldline, the European Fintech or Capital One, the US credit card issuer – both are levered to the reopening of stores and tourism. We also added Volkswagen, which has a cyclical aspect, but we believe is poised to outperform as its line of EV (Electric Vehicles) models ramps up.

Overall, we maintain a liquid and solid portfolio of strong convictions, diversified in terms of geography, sectors and themes. Indeed, at the beginning of 2021, our main thematics revolve around:

- 1) digitalization (38%), with names such as the American fintech company Fiserv and the Asian e-commerce player JD.com
- 2) demographic shifts (30%), with names like the Danish pharmaceutical company Novo Nordisk, the American medical technology company Medtronic
- 3) technology accelerators (23%), with names like the Chinese company Kingsoft Cloud and the American software company Salesforce.

Finally, our constant quest for growth has led us to develop a new theme related to climate change, to participate in particular in the rise of the electric vehicle and the development of renewable energies. But we remain very selective in this thematic as investors interest has been growing very quickly leading to some very stretched valuations.

These disruptive themes have proven to be particularly resistant to a global economic downturn: many of these adoption curves have been sharply accentuated, driving up penetration rates and short-term profits. However, they continue as global economies reopen: consumers and businesses simply continue to embrace the powerful trends of e-commerce, contactless payment, and the use of the cloud, while medical advances continue.

Discover the Fund's webpage:

Carmignac Investissement

Part A EUR ACC code ISIN: FR0010148981 *Reference Indicator: MSCI ACWI (USD) (net dividends reinvested). Past performance is not necessarily indicative of future performance. The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged. Performances are net of fees (excluding possible entrance fees charged by the distributor). As of 01/01/2013, the reference indicators for the shares are calculated net dividends reinvested. Source: Carmignac, 31/12/2020 Risk Scale from the KIID (Key Investor Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Carmignac Investissement E EUR Acc

ISIN: FR0010312660

Aanbevolen minimale beleggingstermijn



Voornaamste risico's van het Fonds

AANDELEN: Aandelenkoersschommelingen, waarvan de omvang afhangt van externe factoren, het kapitalisatieniveau van de markt en het volume van de verhandelde aandelen, kunnen het rendement van het Fonds beïnvloeden.

WISSELKOERS: Het wisselkoersrisico hangt samen met de blootstelling, via directe beleggingen of het gebruik van valutatermijncontracten, aan andere valuta's dan de waarderingsvaluta van het Fonds.

DISCRETIONAIR BEHEER: Het anticiperen op de ontwikkelingen op de financiële markten door de beheermaatschappij is van directe invloed op het rendement van het Fonds, dat afhankelijk is van de geselecteerde effecten.

Het fonds houdt een risico op kapitaalverlies in.

This document is intended for professional clients. This is an advertising document. This document may not be reproduced, in whole or in part, without prior authorisation from the management company. This document does not constitute a subscription offer, nor does it constitute investment advice. The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights in French, English, German, Dutch, Spanish, Italian on the following link:https://www.carmignac.com/en_US. Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The Funds are common funds in contractual form (FCP) conforming to the UCITS Directive under French law. The return may increase or decrease as a result of currency fluctuations, for the shares which are not currencyhedged. The French investment funds (fonds commun de placement or FCP) are common funds in contractual form (FCP) conforming to the UCITS Directive under French law. Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. Access to the Fund may be subject to restrictions with regard to certain persons or countries. The Fund is not registered in North America, in South America, in Asia nor is it registered in Japan. The Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Fund has not been registered under the US Securities Act of 1933. The Fund may not be offered or sold, directly or indirectly, for the benefit or on behalf of a "U.S. person", according to the definition of the US Regulation S and/or FATCA. The Fund presents a risk of loss of capital. The risks and fees are described in the KIID (Key Investor Information Document). The Fund's prospectus, KIIDs and annual reports are available at www.carmignac.com, or upon request to the Management Company. The KIID must be made available to the subscriber prior to subscription. - In Switzerland, the Fund's respective prospectuses, KIIDs and annual reports are available at www.carmignac.ch, or through our representative in Switzerland, CACEIS (Switzerland) S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy 35, 1260 Nyon. - In the United Kingdom, the Funds' respective prospectuses, KIIDs and annual reports are available at www.carmignac.co.uk, or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This material was prepared by Carmignac Gestion and/or Carmignac Gestion Luxembourg and is being distributed in the UK by Carmignac Gestion Luxembourg UK Branch (Registered in England and Wales with number FC031103, CSSF agreement of 10/06/2013). - In Spain: Carmignac Patrimoine is registered with Comisión Nacional del Mercado de Valores de España (CNMV) under number 386, Carmignac Investissement under number 385, Carmignac Sécurité under number 395, Carmignac Emergents under number 387 and Carmignac Portfolio under number 392.